Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 1, 1999, Pages 53-57

  Fleishaker, Joseph C ^a   Mucci, Massimiliano ^a   Pellizzoni, Cinzia ^a   Poggesi, Italo ^a  

^a PFIZER INC   (United States)

Author keywords

Antidepressant; Pharmacokinetics; Stereoisomers

Indexed keywords

REBOXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; URINALYSIS;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MORPHOLINES; REGRESSION ANALYSIS; SEX CHARACTERISTICS; STEREOISOMERISM;

EID: 0032899823     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199901)20:1<53::AID-BDD157>3.0.CO;2-P     Document Type: Article

References (13)

1. P. Melloni, G. Carniel, A. Della Toree, A. Bonsignori, M. Buonamici, O. Pozzi, D. Ricciardi and A. C. Rossi, Potential antidepressant agents. x-Aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem. Chim. Ther., 19, 235-242 (1984).
2. M. Riva, N. Brunello, A. C. Rovescalli, R. Galimberti, N. Carfagna, P. Carminati, O. Pozzi, S. Ricciardi and R. Roncucci, Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J. Drug Dev., 1, 243-253 (1989).
3. S.A. Montgomery, Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. Oxf., 11(4 Suppl.) S9-S15 (1997).
4. M. Mucci, Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. Oxf., 11(4 Suppl.), S33-S37 (1997).
5. D.M. Edwards, C. Pellizzoni, H.P. Breuel, A. Berardi, M.G. Castelli and E. Frigerio et al., Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm. Drug. Dispos., 16, 443-460 (1995).
6. C. Pellizzoni, I. Poggesi, N.P. Jorgensen, D.M. Edwards, E. Paus and M. Strolin-Benedetti, Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm. Drug. Dispos., 17, 623-633 (1996).
7. G. Cocchiara, R. Battaglia, P. Pevarello and M. Strolin-Benedetti, Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur. J. Drug. Metab. Pharmacokin., 16, 231-239 (1991).
8. M. Strolin-Benedetti, E. Frigerio, P. Tocchetti, G. Brianceshi, M. G. Castelli, C. Pellizzoni and P. Dostert, Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality, 7, 285-289 (1995).
9. M. Strolin-Benedetti, C. Pellizzoni, I. Poggesi, P. Dostert, A. Dubini and M. Bosc et al. Pharmacokinetics of reboxetine enantiomers in healthy volunteers. Can. J. Physiol. Pharmacol., 72(Suppl 1: abstract) P13.21.17 (1994).
10. M.S. Allen, M.A. Hamzavi, D.J. Harvan and D.W. Knuth, Chiral LC/MS/MS analysis of reboxetine enantiomers in plasma and urine using postcolumn acidification. Abstract presented at the 46th Annual ASMS Conference on Mass Spectrometry and Allied Topics, Orlando FL, June, 1998.
11. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn., Marcel Dekker, New York, 1982.
12. SAS Institute, Inc. SAS STAT User's Guide, Version 6 Edition, SAS Institute, Inc, Cary, NC, 1990.
13. P. Dostert, M.S. Benedetti and I. Poggesi, Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline re-uptake inhibitor. Eur. Neuropsychopharmacol., 7(Suppl. 1) S23-S35 (1997).